Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
FAQs
Advertise
UsernamePublicRestriction
Tags:
Leadership Business Strategies Companies

Leading A Diverse Company: Biopharma Executives Offer Ways Forward

  • Analysis

Executive Summary

BIO hosted discussions during its annual meeting to reinforce the value of inclusion, offer advice to companies and reflect on recent US events. 

You may also be interested in...



Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity

Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.

10 Non-COVID News Updates To Listen For In Second Quarter Reporting

The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.

Quick Listen: Scrip's Five Must-Know Things

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharma industry.

Table

View full table

Related Content

Scrip

Topics

Related Companies

Tags:
Leadership Business Strategies Companies
UsernamePublicRestriction

Register

SC142399

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By